FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of Age and Older with pNET and epNET By Ogkologos - April 18, 2025 802 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CABINET study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance December 4, 2025 Two Drugs Work Together to Block ‘Master Regulator’ of Breast, Other... September 4, 2018 Preguntas frecuentes sobre el COVID-19 y el cáncer: Respuestas para pacientes... June 25, 2020 Today is Random Acts of Kindness Day February 17, 2021 Load more HOT NEWS Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors Early-onset cancer: why are more young adults being diagnosed? How the National Cancer Act Has Made a Difference in Cancer...
